Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
180
datasets available to search
ShareScore release 0.9.0
Dataset results
180 results for “Polycystic Kidney Disease”
Pretrained network for segmentation of kidneys and exophytic cysts in subjects with autosomal dominant polycystic kidney disease (ADPKD)
<p>This pretrained network based on the 3D U-Net is for segmentation of kidneys and exophytic cysts in subjects with autosomal dominant polycystic kidney disease (ADPKD). The network was trained with 157 (including 53 cases with exophytic cysts) subjects with ADPKD. The details of trained dataset and the performance of the network will be updated after our manuscript is accepted for publication.</p>
Daily Caloric Restriction and Intermittent Fasting in Overweight and Obese Adults With Autosomal Dominant Polycystic Kidney Disease
ClinicalTrials.gov study NCT03342742. IPD Sharing: YES. Countries: 1. Publications: 1.
Data from: Ablation of Hoxb3os in mouse polycystic kidney disease exacerbates cystogenesis
<p>Autosomal dominant polycystic kidney disease (ADPKD) is a monogenic disorder characterized by the formation of cysts in the kidney and is primarily caused by mutations in two genes, <em>PKD1</em> and <em>PKD2</em>. In this study, we investigated the role of the long noncoding RNA (lncRNA) <em>Hoxb3os</em> in ADPKD by ablating its expression in the mouse. <em>Hoxb3os</em>-null mice were viable and had grossly normal kidney morphology but displayed activation of mTOR/Akt signaling and subsequent increase in kidney cell proliferation. To determine the role of <em>Hoxb3os</em> in cystogenesis, we crossed the <em>Hoxb3os</em>-null mouse to two orthologous <em>Pkd1</em> mouse models: <em>Pkhd1/Cre</em>;<em>Pkd1<sup>F/F</sup></em> (rapid cyst progression) and <em>Pkd1<sup>RC/RC</sup></em> (slow cyst progression). Ablation of <em>Hoxb3os</em> exacerbated cyst growth in both models. To gain insight into the mechanism whereby <em>Hoxb3os</em> inhibition promotes cystogenesis, we performed proteomic analysis of mTOR/Akt pathway between <em>Pkd1</em> single-knockout (SKO) and <em>Pkd1-Hoxb3os</em> double-knockout (DKO) mice. Compared to SKO, DKO mice presented with enhanced levels of total and phosphorylated Rictor. This was accompanied by increased phosphorylation of Akt<sup>Ser473</sup>, a known mTORC2 effector site. Physiologically, kidneys from DKO mice displayed between 40-50% increase in cell proliferation. Results from this study indicated that ablation of <em>Hoxb3os</em> in mouse PKD exacerbated cystogenesis and dysregulated mTORC2.</p>
Metabolic Derangement in Polycystic Kidney Disease Mouse Models Is Ameliorated by Mitochondrial-Targeted Antioxidants
<p>Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressively enlarging cysts. Here we elucidate the interplay between oxidative stress, mitochondrial dysfunction, and metabolic derangement using two mouse models of PKD1 mutation, PKD1RC/null and PKD1RC/RC. Mouse kidneys with PKD1 mutation have decreased mitochondrial complexes activity. Targeted proteomics analysis shows a significant decrease in proteins involved in the TCA cycle, fatty acid oxidation (FAO), respiratory complexes, and endogenous antioxidants. Overexpressing mitochondrial-targeted catalase (mCAT) using adeno-associated virus reduces mitochondrial ROS, oxidative damage, ameliorates the progression of PKD and partially restores expression of proteins involved in FAO and the TCA cycle. In human ADPKD cells, inducing mitochondrial ROS increased ERK1/2 phosphorylation and decreased AMPK phosphorylation, whereas the converse was observed with increased scavenging of ROS in the mitochondria. Treatment with the mitochondrial protective peptide, SS31, recapitulates the beneficial effects of mCAT, supporting its potential application as a novel therapeutic for ADPKD.</p>
Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease
ClinicalTrials.gov study NCT04152837. IPD Sharing: NO. Countries: 1. Publications: 1.
HALT Progression of Polycystic Kidney Disease Study A
ClinicalTrials.gov study NCT00283686. IPD Sharing: YES. Countries: 1. Publications: 6.
A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001]
ClinicalTrials.gov study NCT00841568. IPD Sharing: Not stated. Countries: 1. Publications: 2.
The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
ClinicalTrials.gov study NCT03487913. IPD Sharing: NO. Countries: 1. Publications: 0.
Time Restricted Feeding in Autosomal Dominant Polycystic Kidney Disease
ClinicalTrials.gov study NCT04534985. IPD Sharing: YES. Countries: 1. Publications: 2.
Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney Disease
ClinicalTrials.gov study NCT02697617. IPD Sharing: NO. Countries: 1. Publications: 1.
Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease
ClinicalTrials.gov study NCT02160145. IPD Sharing: Not stated. Countries: 22. Publications: 5.
Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease
ClinicalTrials.gov study NCT02656017. IPD Sharing: NO. Countries: 1. Publications: 3.
A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan]
ClinicalTrials.gov study NCT01280721. IPD Sharing: Not stated. Countries: 1. Publications: 1.
8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
ClinicalTrials.gov study NCT01451827. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease)
ClinicalTrials.gov study NCT02964273. IPD Sharing: YES. Countries: 4. Publications: 4.
Effect of Beetroot Juice on Reducing Hypertension in Autosomal Dominant Polycystic Kidney Disease
ClinicalTrials.gov study NCT05401409. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
ClinicalTrials.gov study NCT01853553. IPD Sharing: NO. Countries: 1. Publications: 1.
Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease
ClinicalTrials.gov study NCT00414440. IPD Sharing: Not stated. Countries: 3. Publications: 2.
Pilot Study of Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
ClinicalTrials.gov study NCT00286156. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Tolvaptan Open-label Pilot Efficacy, Tolerability, and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
ClinicalTrials.gov study NCT00413777. IPD Sharing: Not stated. Countries: 1. Publications: 6.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.